drugset / Trial / NCT04263090
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
Phase 1/2
Completed
25 enrolled
Icahn School of Medicine at Mount Sinai
Bristol-Myers Squibb · collabTraws Pharma, Inc. · collab
NaSequentialOpen-labelTreatment
Summary
A Phase1/2a Study of Rigosertib plus Nivolumab in Stage IV Lung Adenocarcinoma Patients with KRAS Mutation who Progressed on First-Line Treatment
Timeline
- Start
- 2020-06-29
- Primary completion
- 2023-12-20
- Completion
- 2023-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | rigosertib | Small molecule | 280 mg | Oral |
| Subject | rigosertib | Small molecule | 560 mg | Oral |